Pitavastatin vs Lovastatin — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

HMG-CoA Reductase Inhibitor

Pitavastatin

Brand: Livalo

First FDA approval: 2017-02-03

HMG-CoA Reductase Inhibitor

Lovastatin

First FDA approval: 2001-12-17

Lowest NADACAcquisition cost floor across all NDCs

$1.16Per unit

$0.038Per unit

Average NADACAcross all dosage forms and strengths

$2.99Up to $10.21

$0.046Up to $0.056

Generic manufacturersActive ANDA holders — FDA Orange Book

824 total ANDAs filed

721 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$182.6MFull year

$38.5MFull year

Part D claims (CY24)Total fills, all strengths

466K159K beneficiaries

3.7M1.2M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$392Per claim, all NDCs

$10Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

103Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes8 manufacturers

Yes7 manufacturers